Update shared on15 Aug 2025
Fair value Decreased 23%Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67.
What's in the News
- Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.
- Board meeting scheduled to consider and approve unaudited financial results for the quarter ended June 30, 2025.
- Announced annual dividend of INR 0.80 per share, payable on September 7, 2025, subject to AGM approval.
- 33rd AGM scheduled to be held via video conferencing; board to consider appointment of M/s Jinesh Dedhia & Associates as Secretarial Auditor.
Valuation Changes
Summary of Valuation Changes for Marksans Pharma
- The Consensus Analyst Price Target has significantly fallen from ₹301.00 to ₹231.67.
- The Consensus Revenue Growth forecasts for Marksans Pharma has significantly fallen from 21.1% per annum to 12.0% per annum.
- The Net Profit Margin for Marksans Pharma has significantly fallen from 18.91% to 16.01%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.